ENA Respiratory

ENA Respiratory

HealthAntiviral Nasal SprayB2G📍 Australia

ENA Respiratory is a clinical-stage biotech company developing an antiviral nasal spray, INNA-051, to strengthen the body's first line of defense against respiratory viruses like influenza, RSV, and COVID-19. This $3 million grant will fund a trial in adults with asthma to assess the treatment's safety and efficacy, aiming to reduce complications from respiratory infections in high-risk groups.

Total raised
Undisclosed
tracked to date
Latest round
Grant
Sep 3, 2026
Known investors
1
led by Biointelect Venturer program

Is this your company?

Claim this profile to get matched with investors who fund Health startups in Australia.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 Australia Funding Report

Read the Q3 2026 Australia report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-australia-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 Australia Funding Report</a>

Funding history

  1. 1
    $2.98 millionGrantSep 3, 2026

    Led by Biointelect Venturer program

    Announcement ↗

Founder

Christophe Demaison
Christophe Demaison
CEO

Investors in ENA Respiratory

Backers from this company's tracked funding rounds.

  • BBiointelect Venturer programLead investorVC firm

ENA Respiratory in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile